NEXPOVIO 20 mg film-coated tablets

DRUG2 trials

Sponsors

University Medical Center Hamburg-Eppendorf, Fondazione IRCCS Istituto Nazionale Dei Tumori

Conditions

Relapsed or Refractory Peripheral T-cell Lymphomasmultiple myeloma

Phase 2

Pilot phase II study of Selinexor in combination with Ifosfamide, Etoposide and Dexamethasone (SIDE) in patients with relapsed or refractory Peripheral T-cell Lymphomas

Active, not recruitingCTIS2024-513295-18-00

Fondazione IRCCS Istituto Nazionale Dei TumoriRelapsed or Refractory Peripheral T-cell Lymphomas

Start: 2022-08-10Target: 30Updated: 2025-11-18

Phase 3

Allogeneic stem cell transplantation vs. conventional therapy as salvage therapy for relapsed / progressive patients with multiple myeloma after a first-line therapy

CompletedCTIS2024-510590-14-00

University Medical Center Hamburg-Eppendorfmultiple myeloma

Start: 2023-03-03End: 2025-01-30Target: 400Updated: 2025-02-05